Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Care Capital: VC Post-2001

This article was originally published in Start Up

Executive Summary

Care Capital's focus on later-stage programs--driven by its ex-Big Pharma partners' own expertise in more advanced development and marketing--happily coincided with the lower-risk, closer-to-market models which have become fashionable with private and public investors since the 2001 downturn. Does this VC firm have the right model at the right time?

You may also be interested in...



Jumpstart to Products

Discovery research is an ever more difficult investment to justify, so companies are placing greater emphasis on mining discoveries that have already been made but whose real value remains unexploited. Big Pharma, in part inhibited by habit and current infrastructure, has not moved aggressively in the new direction-but the jumpstart model now dominates small-company strategies and will increasingly translate into the rest of the industry.

Former Big Pharma Executives See Gold in Consolidation's Cast-Offs

Top executives from Big Pharmas, like Jan Leschley of SmithKline and Tony Wild of Warner-Lambert, are now taking a run at venture capital--figuring that their rolodexes and understanding of drug-company requirements will give them a big advantage in starting new companies. The question is whether these contacts will be of much help during periods when financing is difficult--that's when real VC experience comes in handy.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel